Provided is the use of a WT1 peptide, a polynucleotide encoding said peptide, an expression vector comprising said polynucleotide, or a cell including said expression vector in the manufacture of a medicament for the treatment or prevention of cancer in a subject who is HLA-DPB1*0901 positive, wherein said WT1 peptide has the ability to bind to HLA-DPB1*0901, and is a peptide selected from: (1) a peptide comprising the amino acid sequence Lys Arg Tyr Phe Lys Leu Ser His Leu Gln Met His Ser Arg Lys His ； or (2) a peptide of (1), wherein the amino acid sequence has a substitution, modification or deletion of one to several amino acids.
